blood pressure (BP) despite the use of, at least, three classes of antihypertensive
drugs to keep BP controlled are considered resistant to treatment
[1]. Resistant hypertension (RH) is prevalent in 10 to 30% of all
hypertensive patients, and these patients are more likely to develop
adverse cardiovascular events [2,3]. Thus, the control of BP in resistant
hypertension is a recognized clinical challenge.